The #1 Biotech Investment of the Decade
How this company’s unique timeline is giving them an edge over the competition
When you think of an investing opportunity you missed out on…
What were the factors that led you to pass on it?
Smart investors scour through everything from the stock price…
To the financial statements…
All the way to the CEO of the company.
But if you’re looking to invest in a new biotech company…
The requirements are a bit more complex.
First of all…
Biotech companies are a rare example of how an industry can exist…
With billions of potential consumers…
And only hypothetical products.
It seems insane when you think about it.
But even the fortunes of Jeff Bezos and Bill Gates would pale in comparison to the money that could be made if even one biotech company creates the cure for cancer…
Alzheimer’s…
Parkinson’s…
Or any other catastrophic disease that plagues mankind.
That’s why Bezos and Gates have invested billions into a company called Grail…
Whose mission is to detect cancer early.
With all of the money these two pumped into it…
A rational person would assume that the company already has a viable product…
Or at the very least…
Has made a substantial amount of progress in its research by now.
So it might surprise you to learn that Grail has made exactly ZERO progress…[1]
But it shouldn’t.
Because Grail’s story is not exactly unique…
A staggering 90% of pharmaceuticals fail to even enter FDA trials.[2]
And while there are many reasons a biotech company – and its drugs – can fail…
Two clinically trained pharmacists, turned business executives, believe that they have the keys to be in the 10% of biotechs who succeed…
And with a development timeline as incredible as their combined experience…
The company they’ve called Tharimmune (NASDAQ:THAR)…
Is poised to become one of the biggest biotech opportunities of the decade.
And for those who pass it up…
Possibly one of the biggest investing regrets they’ll ever have.
Beating The Billionaires
So why are the executives at Tharimmune are confident that they will succeed when 90% of their competitors fail?
For starters…
The sterling track record of their CEO Randy Milby and COO Sireesh Appajosyula.
By leveraging their vast business and clinical experience…
There could be no better duo to usher Tharimmune into the spotlight.
Here’s their story:
CEO, Randy Milby began his career in high management positions with both Goldman Sachs and DuPont Merck…
Before he became the CEO of the publicly traded biopharmaceutical company, CorMedix…
Where he turned a $3M company into a $350M venture!
So if there was ever anyone to lead the charge on creating a dynasty out of a fledgling operation, Milby is at the top of a very short list!
And while Milby was outperforming virtually all his peers and helping CorMedix reach its full potential…
COO Sireesh Appajosyula was graduating with his Doctor of Pharmacy from Rutgers University…
And afterwards, spent 8 years in a key management positions with Salix Pharmaceuticals…
A company best known for creating cures for rare gastrointestinal maladies…
Overseeing product commercialization, business development, and medical affairs…
Before becoming a member of the Board of Directors of Tharimmune in 2021.[3]
But why does it matter that Tharimmue is being run by these two men?
Surely other biotech companies have executives with similar backgrounds…
And potential for success?
Otherwise why would the likes of Bill Gates be investing in them?
Short answer: billionaire investors have the money to lose.
And they’re willing to risk some of it on unproven companies working on cures for diseases like cancer…
Simply because the market for a product like that would have billions of potential users…
But Milby and Appajosyula have the experience to know that you don’t have to have the cure for cancer to have a successful biotech company…
Because they have a cure available now that could change the lives of the majority of the 4 million people suffering from liver failure in the US alone…
And Milby and Appajosyula have a plan to deliver this drug in record time!
The Cure Is Already Approved
Picture this…
You’re forced to wear long sleeves or pants in sweltering heat…
Because you spend your nights scratching yourself to ribbons in your sleep.
For 70% of people suffering from liver failure or other liver diseases…
That is their reality.
As their livers fail to function normally…
Bile that should be disposed of is instead deposited under the skin…
Causing what is known as Chronic Pruritus…
A deep, insatiable itch…
That causes those suffering to scratch until they bleed.
But thanks to the leadership of Milby and Appajosyula…
Tharimmune (NASDAQ:THAR) is on the cusp of delivering the cure…
And the drug is already approved by the FDA!
[4]Called Nalmefene…
This drug was first used to treat overdoses nasally and intravenously…
But its unique chemical makeup also makes it the perfect solution to Chronic Pruritus…
And fortunately…
The patent on the drug is specific only to the nasal spray.[5]
So for the experienced executives at Tharimmune…
It simply became a matter of creating a suitable delivery mechanism for the drug…
And what they have developed could mean the end of Chronic Pruritus forever…
All because of a dime-sized oral patch!
The Future Of Biotech Is Here
What is the last thing that an overworked and underperforming liver needs?
Another substance to filter.
Which is why the team at Tharimmune created their small, oral patch…
Designed to easily and discreetly stick to the inside of the cheek…
Delivering relief straight into the bloodstream…
Bypassing the already overworked liver.
And the best part is that unlike other biotech companies…
That often take DECADES to produce a product for testing…[6]
The executives at Tharimmune (NASDAQ:THAR) are working with an unprecedented timeline…
Phase II testing of this patch set to begin at the end of 2024.
And if everything goes according to plan…
Their product could be ready for the shelves as early as the first quarter of 2026!
That’s less than two years away![7]
Music to the ears of biotech investors…
Who may have already been burned by any one of the over 2 dozen biotech companies to file for bankruptcy in 2023 alone…
Like Sorrento Therapeutics:
A company that turned down a billion-dollar buyout in 2020 and was involved in a legal dispute with NantCell’s founder…
Or Humanigen:
A clinical-stage biopharma company who, after failed attempts to sell its assets, filed for bankruptcy protection in 2024…[8]
But with Tharimmune…
Their drug is already approved by the FDA…
And their experienced, accomplished leadership…
Speedy timeline…
And $10 million to spend on Phase II testing…[9]
You could find the golden biotech opportunity you’ve been searching for.
Of course, you should never risk more than you are comfortable losing…
And understand the inherent risks that come with investing in a new company…
But if Tharimmune has the same kind of success as its CEO’s former projects…
It is fairly obvious that you wouldn’t have to bet the farm to make a life changing investment.
Click the link below to learn more about Tharimmune’s mission…
And how you could earn bragging rights in as little as two years!
Click the link below now!
P.S. Still want more information on Tharimmune, Inc. (THAR)?
Sign up below for Tharimmune’s Investor Presentation, and breaking news about this and other interesting companies, completely free. Sign up below to learn about this investment opportunity.
By signing up above, Wall Street Fundamentals will send the latest investor report to the email provided. You'll also receive special reports completely free. You can unsubscribe at any time. View our Privacy Policy here.
IMPORTANT NOTICE AND DISCLAIMER
THIS PUBLICATION IS AN ISSUER-PAID ADVERTISEMENT. This paid advertisement includes a stock profile of Tharimmune Inc. [THAR]. To enhance public awareness of THAR and its securities, the issuer has provided Promethean Marketing, Inc. (“Promethean”) with a total budget of approximately [amount in words] ($[amount]) to cover the costs associated with this advertisement for a period beginning xxx, 2024 and currently set to end xxx, 2024. This compensation should be viewed as a major conflict with our ability to be unbiased. The website hosting this advertisement, Wall Street Fundamentals, is owned by Promethean. As a result of this advertisement, Wall Street Fundamentals may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. Promethean will retain any excess sums after all expenses are paid. As of the date this advertisement is posted to the Wall Street Fundamentals website, some or all of Promethean or Wall Street Fundamentals and any of their respective officers, principals, or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) may hold the securities of THAR and may sell those shares during the course of this advertising campaign. This advertisement may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of THAR, increased trading volume, and possibly an increased share price of THAR’s securities, which may or may not be temporary and decrease once the advertising campaign has ended. This communication is based on information generally available to the public and on interviews with THAR Management, and does not (to the Publisher’s knowledge, as confirmed by THAR) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, neither Promethean or Wall Street Fundamentals cannot guarantee the accuracy or completeness of the information. To more fully understand the Wall Street Fundamentals website or service, please review its full Disclaimer and Disclosure Policy located at https://wallstreetfundamentals.com/legal-disclaimer/
[1] https://www.geekwire.com/2020/bill-gates-jeff-bezos-backed-cancer-detection-company-grail-led-ex-juno-ceo-files-ipo/
[2] https://www.linkedin.com/pulse/fail-fast-often-forward-lessons-biotech-innovation-resilience-bose-6cpce/
[3] https://tharimmune.com/about/#1589207090757-b03babc1-bbc8
[4] https://ir.tharimmune.com/wp-content/uploads/2024/01/THAR-Corp-Presentation-January-2024.pdf
[5] https://www.pharmaceutical-technology.com/data-insights/purdue-pharma-gets-grant-for-parenteral-formulation-for-rapid-opioid-overdose-treatment/#:~:text=Purdue%20Pharma%20has%20patented%20a,within%205%20minutes%20post%2Dinjection.
[6] https://matchtrial.health/en/how-long-does-it-take-to-develop-a-new-drug/#:~:text=The%20process%20of%20developing%20a,based%20on%20their%20pharmacological%20properties.
[7] https://ir.tharimmune.com/wp-content/uploads/2024/01/THAR-Corp-Presentation-January-2024.pdf
[8] https://www.fiercebiotech.com/special-reports/biotech-bankruptcies-break-10-year-record-2023
[9] https://ir.tharimmune.com/wp-content/uploads/2024/01/THAR-Corp-Presentation-January-2024.pdf